01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
retatrutide glp-1 receptor agonist Retatrutide, a GIP, and glucagon agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA 𧬠Retatrutide Explained Retatrutide is
Description
GLP-1s are safe and effective for most people in the short to medium term, but we dont have long-term data to be sure theyre not causing severe adverse effects elsewhere
Faika, M
It works through a 4-phase approach designed to optimize your metabolism, reduce inflammation, and promote lasting weight loss results
They may suggest more frequent vision checks
These side effects included: Vomiting The researchers highlighted that these symptoms were generally of mild to moderate severity
I felt no extra side effects from adding it
